Cargando…

Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients

The presence of tumor budding (TuB) at the invasive front of rectal cancers is a valuable indicator of tumor aggressiveness. Tumor buds, typically identified as single cells or small tumor cell clusters detached from the main tumor body, are characterized by loss of cell adhesion, increased migrator...

Descripción completa

Detalles Bibliográficos
Autores principales: Zlobec, Inti, Borner, Markus, Lugli, Alessandro, Inderbitzin, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415098/
https://www.ncbi.nlm.nih.gov/pubmed/22900161
http://dx.doi.org/10.1155/2012/795945
_version_ 1782240317567664128
author Zlobec, Inti
Borner, Markus
Lugli, Alessandro
Inderbitzin, Daniel
author_facet Zlobec, Inti
Borner, Markus
Lugli, Alessandro
Inderbitzin, Daniel
author_sort Zlobec, Inti
collection PubMed
description The presence of tumor budding (TuB) at the invasive front of rectal cancers is a valuable indicator of tumor aggressiveness. Tumor buds, typically identified as single cells or small tumor cell clusters detached from the main tumor body, are characterized by loss of cell adhesion, increased migratory, and invasion potential and have been referred to as malignant stem cells. The adverse clinical outcome of patients with a high-grade TuB phenotype has consistently been demonstrated. TuB is a category IIB prognostic factor; it has yet to be investigated in the prospective setting. The value of TuB in oncological and pathological practice goes beyond its use as a simple histomorphological marker of tumor aggressiveness. In this paper, we outline three situations in which the assessment of TuB may have direct implications on treatment within the multidisciplinary management of patients with rectal cancer: (a) patients with TNM stage II (i.e., T3/T4, N0) disease potentially benefitting from adjuvant therapy, (b) patients with early submucosally invasive (T1, sm1-sm3) carcinomas at a high risk of nodal positivity and (c) the role of intratumoral budding assessed in preoperative biopsies as a marker for lymph node and distant metastasis thus potentially aiding the identification of patients suitable for neoadjuvant therapy.
format Online
Article
Text
id pubmed-3415098
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34150982012-08-16 Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients Zlobec, Inti Borner, Markus Lugli, Alessandro Inderbitzin, Daniel Int J Surg Oncol Review Article The presence of tumor budding (TuB) at the invasive front of rectal cancers is a valuable indicator of tumor aggressiveness. Tumor buds, typically identified as single cells or small tumor cell clusters detached from the main tumor body, are characterized by loss of cell adhesion, increased migratory, and invasion potential and have been referred to as malignant stem cells. The adverse clinical outcome of patients with a high-grade TuB phenotype has consistently been demonstrated. TuB is a category IIB prognostic factor; it has yet to be investigated in the prospective setting. The value of TuB in oncological and pathological practice goes beyond its use as a simple histomorphological marker of tumor aggressiveness. In this paper, we outline three situations in which the assessment of TuB may have direct implications on treatment within the multidisciplinary management of patients with rectal cancer: (a) patients with TNM stage II (i.e., T3/T4, N0) disease potentially benefitting from adjuvant therapy, (b) patients with early submucosally invasive (T1, sm1-sm3) carcinomas at a high risk of nodal positivity and (c) the role of intratumoral budding assessed in preoperative biopsies as a marker for lymph node and distant metastasis thus potentially aiding the identification of patients suitable for neoadjuvant therapy. Hindawi Publishing Corporation 2012 2012-07-31 /pmc/articles/PMC3415098/ /pubmed/22900161 http://dx.doi.org/10.1155/2012/795945 Text en Copyright © 2012 Inti Zlobec et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Zlobec, Inti
Borner, Markus
Lugli, Alessandro
Inderbitzin, Daniel
Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients
title Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients
title_full Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients
title_fullStr Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients
title_full_unstemmed Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients
title_short Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients
title_sort role of intra- and peritumoral budding in the interdisciplinary management of rectal cancer patients
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415098/
https://www.ncbi.nlm.nih.gov/pubmed/22900161
http://dx.doi.org/10.1155/2012/795945
work_keys_str_mv AT zlobecinti roleofintraandperitumoralbuddingintheinterdisciplinarymanagementofrectalcancerpatients
AT bornermarkus roleofintraandperitumoralbuddingintheinterdisciplinarymanagementofrectalcancerpatients
AT luglialessandro roleofintraandperitumoralbuddingintheinterdisciplinarymanagementofrectalcancerpatients
AT inderbitzindaniel roleofintraandperitumoralbuddingintheinterdisciplinarymanagementofrectalcancerpatients